1,140 reports of this reaction
2.6% of all OSELTAMIVIR PHOSPHATE reports
#6 most reported adverse reaction
INFLUENZA is the #6 most commonly reported adverse reaction for OSELTAMIVIR PHOSPHATE, manufactured by Genentech, Inc.. There are 1,140 FDA adverse event reports linking OSELTAMIVIR PHOSPHATE to INFLUENZA. This represents approximately 2.6% of all 43,488 adverse event reports for this drug.
Patients taking OSELTAMIVIR PHOSPHATE who experience influenza should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFLUENZA is a less commonly reported adverse event for OSELTAMIVIR PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to influenza, the following adverse reactions have been reported for OSELTAMIVIR PHOSPHATE:
The following drugs have also been linked to influenza in FDA adverse event reports:
INFLUENZA has been reported as an adverse event in 1,140 FDA reports for OSELTAMIVIR PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFLUENZA accounts for approximately 2.6% of all adverse event reports for OSELTAMIVIR PHOSPHATE, making it a notable side effect.
If you experience influenza while taking OSELTAMIVIR PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.